Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SORAYA phase 3 single-arm mirvetuximab soravtansine study in FRα-high platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer
MOH_2020-10-27_009447Phase 3Active, not recruiting
- Sponsor
- ImmunoGen
- Start
- Sep 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mirvetuximab soravtansine in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by ImmunoGen. Started Sep 2020; status: active, not recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2020-10-27_009447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-27_009447.